Company Filing History:
Years Active: 2023
Title: **Innovative Contributions of Ruijing Huang in Biopharmaceuticals**
Introduction
Ruijing Huang is a prominent inventor based in Shanghai, China, known for his contributions to the field of biological pharmacy. With a focus on biopharmaceutical innovations, he has developed a significant patent that addresses critical issues in drug formulation and delivery.
Latest Patents
Huang holds a patent for the **HM-3 fusion protein and application thereof**. This invention falls under the technical domain of biological pharmacy and presents a novel long-acting HM-3 fusion protein molecule. The innovation involves linking an active polypeptide HM-3 and its derivatives to a human Fc (IgG) fragment or a mutant fragment, effectively creating a new molecular entity. The general formula encompasses variations such as (HM-3)-Linker-Fc(IgG) and Fc(IgG)-Linker-(HM-3). Notably, this fusion protein prolongs the half-life of HM-3, reduces costs, and addresses the druggability issues associated with small peptides. It presents potential therapeutic applications for autoimmune diseases, neovascular diseases, and osteoarthritis.
Career Highlights
Huang is affiliated with **Tasly Biopharmaceuticals Co., Ltd.**, where he continues to push the boundaries of medical research and innovation. His work not only enhances the understanding of fusion proteins but also paves the way for new treatments in critical health sectors.
Collaborations
In his pursuit of innovation, Ruijing Huang collaborates with esteemed colleagues, including Baoqing Fan and Jian Li. Their collective expertise in biopharmaceutical research is instrumental in advancing the development of new therapies and solutions in the industry.
Conclusion
Ruijing Huang's patent for the HM-3 fusion protein signifies a substantial advancement in biopharmaceutical technology. His innovations carry the promise of improving treatment options for various diseases, showcasing his commitment to enhancing human health through scientific research. As he continues to collaborate with fellow researchers at Tasly Biopharmaceuticals Co., Ltd., Huang's contributions are sure to leave a lasting impact on the field of medicine.